Cargando…
Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian ter...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832354/ https://www.ncbi.nlm.nih.gov/pubmed/26195199 http://dx.doi.org/10.1002/cncr.29548 |
_version_ | 1782427242020732928 |
---|---|
author | Sawka, Anna M. Straus, Sharon Rodin, Gary Heus, Lineke Brierley, James D. Tsang, Richard W. Rotstein, Lorne Ezzat, Shereen Segal, Phillip Gafni, Amiram Thorpe, Kevin E. Goldstein, David P. |
author_facet | Sawka, Anna M. Straus, Sharon Rodin, Gary Heus, Lineke Brierley, James D. Tsang, Richard W. Rotstein, Lorne Ezzat, Shereen Segal, Phillip Gafni, Amiram Thorpe, Kevin E. Goldstein, David P. |
author_sort | Sawka, Anna M. |
collection | PubMed |
description | BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian tertiary/quaternary care center, early‐stage thyroid cancer patients from a P‐DA trial were contacted 15 to 23 months after randomization/radioactive iodine (RAI) decision making to evaluate longer term outcomes. It was previously reported that the use of the computerized P‐DA in thyroid cancer patients considering postsurgical RAI treatment significantly improved medical knowledge in comparison with usual care alone. The P‐DA and control groups were compared for the following outcomes: feeling informed about the RAI treatment choice, decision satisfaction, decision regret, cancer‐related worry, and physician trust. In a subgroup of 20 participants, in‐depth interviews were conducted for a qualitative analysis. RESULTS: Ninety‐five percent (70 of 74) of the original population enrolled in follow‐up at a mean of 17.1 months after randomization. P‐DA users perceived themselves to be significantly more 1) informed about the treatment choice (P = .008), 2) aware of options (P = .009), 3) knowledgeable about treatment benefits (P = .020), and 4) knowledgeable about treatment risks/side effects (P = .001) in comparison with controls. There were no significant group differences in decision satisfaction (P = .142), decision regret (P = .199), cancer‐related worry (P = .645), mood (P = .211), or physician trust (P = .764). In the qualitative analysis, the P‐DA was perceived to have increased patient knowledge and confidence in decision making. CONCLUSIONS: The P‐DA improved cancer survivors’ actual and long‐term perceived medical knowledge with no adverse effects. More research on the long‐term outcomes of P‐DA use is needed. Cancer 2015;121:3717–3726. © 2015 American Cancer Society. |
format | Online Article Text |
id | pubmed-4832354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-48323542016-04-20 Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial Sawka, Anna M. Straus, Sharon Rodin, Gary Heus, Lineke Brierley, James D. Tsang, Richard W. Rotstein, Lorne Ezzat, Shereen Segal, Phillip Gafni, Amiram Thorpe, Kevin E. Goldstein, David P. Cancer Original Articles BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian tertiary/quaternary care center, early‐stage thyroid cancer patients from a P‐DA trial were contacted 15 to 23 months after randomization/radioactive iodine (RAI) decision making to evaluate longer term outcomes. It was previously reported that the use of the computerized P‐DA in thyroid cancer patients considering postsurgical RAI treatment significantly improved medical knowledge in comparison with usual care alone. The P‐DA and control groups were compared for the following outcomes: feeling informed about the RAI treatment choice, decision satisfaction, decision regret, cancer‐related worry, and physician trust. In a subgroup of 20 participants, in‐depth interviews were conducted for a qualitative analysis. RESULTS: Ninety‐five percent (70 of 74) of the original population enrolled in follow‐up at a mean of 17.1 months after randomization. P‐DA users perceived themselves to be significantly more 1) informed about the treatment choice (P = .008), 2) aware of options (P = .009), 3) knowledgeable about treatment benefits (P = .020), and 4) knowledgeable about treatment risks/side effects (P = .001) in comparison with controls. There were no significant group differences in decision satisfaction (P = .142), decision regret (P = .199), cancer‐related worry (P = .645), mood (P = .211), or physician trust (P = .764). In the qualitative analysis, the P‐DA was perceived to have increased patient knowledge and confidence in decision making. CONCLUSIONS: The P‐DA improved cancer survivors’ actual and long‐term perceived medical knowledge with no adverse effects. More research on the long‐term outcomes of P‐DA use is needed. Cancer 2015;121:3717–3726. © 2015 American Cancer Society. John Wiley and Sons Inc. 2015-07-20 2015-10-15 /pmc/articles/PMC4832354/ /pubmed/26195199 http://dx.doi.org/10.1002/cncr.29548 Text en © 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Sawka, Anna M. Straus, Sharon Rodin, Gary Heus, Lineke Brierley, James D. Tsang, Richard W. Rotstein, Lorne Ezzat, Shereen Segal, Phillip Gafni, Amiram Thorpe, Kevin E. Goldstein, David P. Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title | Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title_full | Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title_fullStr | Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title_full_unstemmed | Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title_short | Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial |
title_sort | thyroid cancer patient perceptions of radioactive iodine treatment choice: follow‐up from a decision‐aid randomized trial |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832354/ https://www.ncbi.nlm.nih.gov/pubmed/26195199 http://dx.doi.org/10.1002/cncr.29548 |
work_keys_str_mv | AT sawkaannam thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT straussharon thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT rodingary thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT heuslineke thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT brierleyjamesd thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT tsangrichardw thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT rotsteinlorne thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT ezzatshereen thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT segalphillip thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT gafniamiram thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT thorpekevine thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial AT goldsteindavidp thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial |